Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery
Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery
复制标题
DOI：
10.1093/jjco/hyy003
复制
发表时间：
2018-03-01
影响因子：
2.4
通讯作者：
Kiura, Katsuyuki
中科院分区：
文献类型：
--
作者：
Makimoto, Go;Kubo, Toshio;Kiura, Katsuyuki
局部晚期非小细胞肺癌(LA-NSCLC)患者的标准治疗方法是放化疗(CRT)，但诱导CRT后的手术切除可以延长特定人群的总生存期。然而，存活时间较长的患者有患第二原发癌(SPC)的风险。这是首次报道LA-NSCLC患者在接受三联式治疗后发生SPC的情况。1997年10月至2013年10月，112例III期非小细胞肺癌患者在本院接受了三联疗法。5年总生存率为71.8%。在112例患者中，有10例在开始CRT后0.60-15.0年(中位数5.49)发生SPC。据观察，SPC的发病率为1.8/100病人年。虽然三联疗法可以延长患者的生存期，但估计SPC的发病率并没有增加。需要一项具有较长随访时间的大型前瞻性研究来确定三模式治疗的效果，包括SPC的发展。
The standard treatment for patients with locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT), but surgical resection following induction CRT can extend overall survival in a select population. However, patients who survive longer are at risk of developing a second primary cancer (SPC). This is the first report to determine the incidence of SPC in survivors with LA-NSCLC after trimodal therapy. Between October 1997 and October 2013, 112 Stage III NSCLC patients underwent trimodal therapy in our hospital. The 5-year overall survival rate was 71.8%. SPC developed in 10 of the 112 patients 0.60-15.0 (median 5.49) years after initiating CRT. The observed incidence of SPC was 1.8 per 100 patient-years. Although trimodal therapy can prolong patient survival, the estimated incidence of SPC does not increase. A large prospective study with a longer follow-up time is required to determine the effects of trimodal therapy, including the development of SPC.